Financial Statement Composition 4 Ugly Truth About Financial Statement Composition
FLORHAM PARK, N.J., May 13, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy aggregation developing atypical blight therapies and communicable ache vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today appear its banking after-effects for the aboriginal division assured March 31, 2020 and provided a business update.
First Division 2020 and Recent Business Highlights
— Accomplished atypical vaccine development programs for COVID-19 and accepted influenza; — Appear pre-clinical accord with Farmacore Biotechnology for tuberculosis; — Delayed admission of Phase 2 VERSATILE-002 balloon for PDS0101 in recurrent/metastatic arch and close blight due to the all-around COVID-19 pandemic; — Secured the U.S. agreement of bulk apparent for the Versamune® platform; — Expanded the ahead appear Cooperative Analysis and Development Agreement with the National Blight Institute to accommodate preclinical and analytic development of PDS0103; — Appointed Kamil Ali-Jackson, Esq. and Dr. Ilian Iliev to the Board of Directors; and — Successfully completed an underwritten accessible alms of our accepted banal in February 2020 with net accretion of about $11.9 actor afterwards deducting underwriting discounts and commissions, not including added alms expenses.
“We accept connected to advantage the versatility and ascendancy of our Versamune® platform, as we aggrandize our development affairs to accommodate vaccines to assure adjoin communicable diseases such as COVID-19 and influenza. We accept that Versamune’s® adeptness to abet a above ambit of careful allowed responses – including acrid antibodies, analgesic T-cells and anamnesis T-cells – abnormally positions PDS to advance added able vaccines to accommodate abiding aegis adjoin the advance of agents with communicable potential. We accept afresh accomplished pre-clinical testing for our COVID-19 vaccine candidates and are in alive discussions with both government agencies and NGOs to actuate the best active aisle forward,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech.
“We abide committed to our immuno-oncology programs, including two accessible Phase 2 studies for PDS0101 with our ally at the National Blight Institute. We additionally attending advanced to initiating our third Phase 2 affairs evaluating the aggregate of PDS0101 and Merck’s KEYTRUDA® in HPV16-associated arch and close blight for aboriginal band analysis of recurrent/metastatic ache back altitude to conduct the abstraction improve,” Dr. Bedu-Addo concluded.
First Division 2020 Banking Review
For the aboriginal division of 2020, net accident was about $4.0 million, or $0.39 per basal allotment and $0.39 per adulterated share, compared to a net assets of about $6.8 million, or $1.82 per basal allotment and $1.47 per adulterated allotment for the aboriginal division of 2019 accompanying to the about-face alliance transaction with Edge Therapeutics.
Research and development costs totaled about $1.9 actor for the aboriginal division of 2020, compared to about $1.0 actor for the aforementioned aeon in 2019, an access of 91%.
For the aboriginal division of 2020, accepted and authoritative costs were about $2.1 actor compared with about $3.9 actor for the aboriginal division of 2019, a abatement of 47%.
Total operating costs for the aboriginal division of 2020 were about $4.0 million, compared to absolute operating costs of about $4.9 actor for the aforementioned aeon in 2019, a abatement of 18%.
As of March 31, 2020, the Company’s banknote antithesis was about $21.0 million. This bulk includes the about $11.9 actor in net accretion afterwards deducting underwriting discounts and commissions, not including added alms costs from PDS Biotech’s underwritten accessible alms including the exercise of the underwriters’ overallotment option, which bankrupt on February 14, 2020.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy aggregation with a growing activity of blight immunotherapies and communicable ache vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® finer delivers disease-specific antigens for in vivo uptake and processing, while additionally activating the analytical blazon 1 interferon immunological pathway, consistent in assembly of almighty disease-specific analgesic T-cells as able-bodied as acrid antibodies. PDS Biotech has engineered assorted therapies, based on combinations of Versamune® and disease-specific antigens, advised to alternation the allowed arrangement to bigger admit ache beef and finer advance and abort them. To apprentice more, amuse appointment www.pdsbiotech.com or chase us on Twitter at @PDSBiotech.
Forward Looking Statements
This advice contains advanced statements (including aural the acceptation of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) apropos PDS Biotechnology Corporation (the “Company”) and added matters. These statements may altercate goals, intentions and expectations as to approaching plans, trends, events, after-effects of operations or banking condition, or otherwise, based on accepted behavior of the Company’s management, as able-bodied as assumptions fabricated by, and advice currently accessible to, management. Advanced statements about accommodate statements that are predictive in attributes and depend aloft or accredit to approaching contest or conditions, and accommodate words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and added agnate expressions amid others. Statements that are not absolute facts are advanced statements. Advanced statements are based on accepted behavior and assumptions that are accountable to risks and uncertainties and are not guarantees of approaching performance. Absolute after-effects could alter materially from those independent in any advanced account as a aftereffect of assorted factors, including, after limitation: the Company’s adeptness to assure its bookish acreage rights; the Company’s advancing basal requirements, including the Company’s advancing banknote aerodrome and the Company’s accepted expectations apropos its affairs for approaching disinterestedness financings; the timing for the Aggregation or its ally to admit the planned analytic trials for its advance assets, PDS0101; the Company’s estimation of the after-effects of its Phase 1 balloon for PDS0101 and whether such after-effects are acceptable to abutment added trials or the approaching success of such trials; the acknowledged accomplishing of the Company’s analysis and development programs and collaborations, including any accord studies apropos PDS0101 and the Company’s estimation of the after-effects and allegation of such programs and collaborations and whether such after-effects are acceptable to abutment the approaching success of the Company’s artefact candidates; the accepting by the bazaar of the Company’s artefact candidates, if approved; the timing of and the Company’s adeptness to access and advance U.S. Food and Drug Administration or added authoritative ascendancy approval of, or added activity with account to, the Company’s artefact candidates; and added factors, including legislative, regulatory, political and bread-and-butter developments not aural the Company’s control, including abrupt affairs or added disruptions to accustomed business operations arising from or accompanying to COVID-19. The above analysis of important factors that could account absolute contest to alter from expectations should not be construed as all-embracing and should be apprehend in affiliation with statements that are included herein and elsewhere, including the accident factors included in the Company’s anniversary and alternate letters filed with the SEC. The advanced statements are fabricated alone as of the date of this columnist absolution and, except as appropriate by applicative law, the Aggregation undertakes no obligation to alter or amend any advanced statement, or to accomplish any added advanced statements, whether as a aftereffect of new information, approaching contest or otherwise.
Media & Investor Relations Contact:
Deanne RandolphPDS BiotechPhone: 1 (908) 517-3613Email: email@example.com
Tram Bui / Alexander LoboThe Ruth GroupPhone: 1 (646) 536-7035 / 1 (646) 536-7037Email: firstname.lastname@example.org / email@example.com
(Financial Statements to Follow)
PDS BIOTECHNOLOGY CORPORATION
Consolidated Antithesis Sheets
Balance Sheets March 31, December 31, 2020 2019 ASSETS Accepted assets: Banknote and banknote equivalents 21,037,806 12,161,739 Prepaid costs and added accepted assets 2,879,378 2,308,462 ———– – ———– – Absolute accepted assets 23,917,184 14,470,201 Acreage and equipment, net 17,149 21,051 ———– – ———– – Absolute assets 23,934,333 14,491,252 ———– – ———– – LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accepted liabilities: Accounts payable 2,556,703 1,197,720 Accrued costs 1,220,191 1,097,640 Restructuring assets 269,887 498,185 ———– – ———– – Absolute accepted liabilities 4,046,781 2,793,545 ———– – ———– – Absolute liabilities: 4,046,781 2,793,545 ———– – ———– – STOCKHOLDERS’ EQUITY Accepted stock, $0.00033 par value, 75,000,000 shares accustomed at March 31, 2020 and December 31, 2019, 15,350,445 shares and 5,281,237 shares issued and 5,064 1,742 outstanding at March 31, 2020 and December 31, 2019, appropriately Added paid-in basal 52,805,601 40,633,670 Accumulated arrears (32,923,113 ) (28,937,705 ) ———– – ———– – Absolute stockholders’ disinterestedness 19,887,552 11,697,707 ———– – ———– – Absolute liabilities and stockholders’ disinterestedness 23,934,333 14,491,252 ———– – ———– –
PDS BIOTECHNOLOGY CORPORATION
Consolidated Statements of Operations and Absolute Loss
Three Months Three Months Assured Ended March 31, March 31, 2020 2019 Operating expenses: Analysis and development costs 1,971,679 1,030,003 Accepted and authoritative costs 2,060,148 3,905,877 ———- – ———- – Absolute operating costs 4,031,827 4,935,880 ———- – ———- – Accident from operations (4,031,827 ) (4,935,880 ) Added assets (expense): Accretion on arrangement acquirement – 11,729,882 Interest assets 46,419 23,302 Interest amount – (606 ) ———- – ———- – Net (loss) and absolute accretion (3,985,408 ) 6,816,698 ———- – ———- – Per allotment information: Net assets (loss) per share, basal and adulterated (0.39 ) 1.82 ———- – ———- – Net assets (loss) per share, adulterated (0.39 ) 1.47 ———- – ———- – Weighted boilerplate accepted shares outstanding, basal and adulterated 10,314,761 3,748,325 ———- – ———- – Weighted boilerplate accepted shares outstanding, adulterated 10,314,761 4,625,295 ———- – ———- –
Financial Statement Composition 4 Ugly Truth About Financial Statement Composition – financial statement composition
| Pleasant in order to the weblog, with this time period I am going to teach you about keyword. Now, here is the very first photograph: